|
Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer. |
2013 |
Med Lett Drugs Ther |
pmid:24043217
|
Mihály Z and Gyõrffy B |
[HER2-positive breast cancer: available targeted agents and biomarkers for therapy response]. |
2013 |
Magy Onkol |
pmid:24107820
|
Dank M and Tõkés T |
[Monoclonal antibody therapy in breast cancer]. |
2013 |
Magy Onkol |
pmid:24107821
|
Segraves NL et al. |
An isolable acyclic hemiacetal of ansamitocin P-3. |
2012 |
Magn Reson Chem |
pmid:22374862
|
Meng H et al. |
A Smart Nano-Prodrug Platform with Reactive Drug Loading, Superb Stability, and Fast Responsive Drug Release for Targeted Cancer Therapy. |
2017 |
Macromol Biosci |
pmid:28464449
|
Storz U |
Antibody-drug conjugates: Intellectual property considerations. |
2015 |
MAbs |
pmid:26292154
|
Panowski S et al. |
Site-specific antibody drug conjugates for cancer therapy. |
2014 Jan-Feb |
MAbs |
pmid:24423619
|
Beck A and Reichert JM |
Antibody-drug conjugates: present and future. |
2014 Jan-Feb |
MAbs |
pmid:24423577
|
Whiteman KR et al. |
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. |
2014 Mar-Apr |
MAbs |
pmid:24492307
|
Chen L et al. |
In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate. |
2016 |
MAbs |
pmid:27380163
|
Beck A et al. |
World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany. |
2011 Jul-Aug |
MAbs |
pmid:21691144
|
Lutz RJ and Whiteman KR |
Antibody-maytansinoid conjugates for the treatment of myeloma. |
2009 Nov-Dec |
MAbs |
pmid:20068397
|
Beck A et al. |
Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany. |
2012 Nov-Dec |
MAbs |
pmid:22909934
|
Thudium K et al. |
American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA. |
2013 Jan-Feb |
MAbs |
pmid:23255090
|
Catcott KC et al. |
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. |
2016 |
MAbs |
pmid:26752675
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. |
2014 |
Lancet Oncol. |
pmid:24793816
|
Gnant M et al. |
HER2-positive breast cancer: a new piece of the puzzle. |
2014 |
Lancet Oncol. |
pmid:24793817
|
Krop IE et al. |
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526538
|
Diéras V et al. |
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. |
2017 |
Lancet Oncol. |
pmid:28526536
|
Thuss-Patience PC et al. |
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. |
2017 |
Lancet Oncol. |
pmid:28343975
|